Ecusson de la République et du canton de Genève


Changer la couleur des liensDiminuer la taille du texteAugmenter la taille du texteImprimer la page > Why Geneva

Geneva-based Endosense signs an international exclusive distribution partnership with Biotronik


BIOTRONIK SE & Co. KG, a leading manufacturer of implantable cardiac devices and pioneer of wireless remote monitoring technologies will be the exclusive distributor of Endosense's  force-sensing ablation catheter, the TactiCath® in all major markets outside of the United States, Japan and Asia.It is the first catheter to give physicians a real-time, objective measure of contact force during cardiac ablation procedures."The extensive clinical study and initial clinical use of the TactiCath have proven its potential to significantly improve the efficacy, safety and reproducibility of catheter ablation procedures, an achievement that is consistent with our commitment to drive positive change in clinical practice. The technology and the Swiss engineering quality match well with our corporate strategy for quality and innovation,” commented Marlou Janssen, global vice president, marketing & sales CRM of BIOTRONIK SE & Co. KG.“We expect the new partnership between Endosense and BIOTRONIK to boost the commercial adoption of the TactiCath," said Eric Le Royer, president and chief executive officer of Endosense. “BIOTRONIK has all the attributes to contribute to this success with shared values, a proven track record and a very established presence in the market. (…)” The Geneva-based start-up company Endosense closed a USD 36 million series B financing in August 2009 with participation from Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.For further information, visit

This page of content is part of the files of this website. We preserve this content to provide information on historical basis. Therefore it is not updated.